AOR:LSE-Rua Life Sciences Plc (GBX)

COMMON STOCK | Biotechnology | LSE

Last Closing Price

GBX 126.50

Change

0.00 (0.00)%

Market Cap

GBX 0.02B

Volume

0.06M

Avg Analyst Target

N/A

Avg User Target

GBX
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Rua Life Sciences Plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in the United Kingdom. The company operates as a contract developer and manufacturer of medical devices; and licensor of Elast-Eon and ECSil implantable co-polymers used in cardiology and urological applications, including pacing leads, cardiac cannulae, and stent devices, as well as Reaction Injection Molding technology for use in high-precision medical device components. It also develops bore polymer sealed grafts and soft tissue patches; and tri leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to Rua Life Sciences Plc in June 2020. Rua Life Sciences Plc was incorporated in 1996 and is based in Glasgow, the United Kingdom.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
HCM:LSE HUTCHMED (China) Limited

+41.00 (+7.64%)

GBX4.88B 17.41 N/A
GNS:LSE Genus plc

+140.00 (+2.58%)

GBX3.53B 73.03 35.08
ABC:LSE Abcam plc

+30.00 (+2.31%)

GBX2.96B 247.50 93.47
OXB:LSE Oxford Biomedica plc

+22.00 (+1.66%)

GBX1.09B N/A 255.32
PRTC:LSE PureTech Health plc

-7.50 (-2.23%)

GBX0.97B 225.00 26.24
ERGO:LSE Ergomed plc

+25.00 (+2.14%)

GBX0.56B 59.38 30.77
SLN:LSE Silence Therapeutics plc

-4.00 (-0.65%)

GBX0.55B N/A N/A
AVCT:LSE Avacta Group Plc

-1.00 (-0.78%)

GBX0.33B N/A N/A
SNG:LSE Synairgen plc

-2.00 (-1.30%)

GBX0.31B N/A N/A
VRP:LSE Verona Pharma plc

N/A

GBX0.23B N/A N/A

ETFs Containing AOR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 396.08% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 396.08% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 94.34% N/A N/A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 94.34% N/A N/A 92% A-
Risk Return Profile  
Volatility (Standard Deviation) 123.16% N/A N/A 11% F
Risk Adjusted Return 76.60% N/A N/A 67% D+
Market Capitalization 0.02B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 9.78 N/A N/A N/A N/A
Price / Cash Flow Ratio -46.75 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -17.53% N/A N/A N/A N/A
Return on Invested Capital -35.68% N/A N/A N/A N/A
Return on Assets -12.71% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.28 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.